TP53 and diffuse large B-cell lymphoma: There is no consensus on the treatment for these patients and treatment remains empirical.<h4>Case report</h4>We reported a case of an elderly R/R DLBCL patient who had <i>TP53</i> mutation and relapsed 12 months after initial response to CAR T-cell therapy.